We are live on
!
Find out more
TD Asset Management Portfolio holdings
AUM
$123B
1-Year Est. Return
34.51%
This Fund
S&P 500
This Quarter
Est. Return
+8.84%
1 Year Est. Return
+34.51%
3 Year Est. Return
+98.94%
5 Year Est. Return
+122.3%
10 Year Est. Return
+375.56%
AUM
$82.9B
AUM Growth
+$1.82B
(+2.3%)
Cap. Flow
-$3.2B
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
27.48%
Holding
1,503
New
58
Increased
633
Reduced
567
Closed
76
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$256M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$156M |
| 4 |
Franco-Nevada
FNV
|
+$115M |
| 5 |
NVIDIA
NVDA
|
+$115M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Pacific Kansas City
CP
|
+$990M |
| 2 |
Pfizer
PFE
|
+$226M |
| 3 |
Amazon
AMZN
|
+$224M |
| 4 |
Johnson & Johnson
JNJ
|
+$220M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$220M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.76% |
| 2 | Financials | 19.43% |
| 3 | Healthcare | 10.94% |
| 4 | Consumer Discretionary | 8.03% |
| 5 | Communication Services | 7.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Fate Therapeutics
FATE
$296M
| $404K | ﹤0.01% |
70,826
| – | – |
|
1302
Sociedad Química y Minera de Chile
SQM
$19.2B
| $391K | ﹤0.01% |
+4,828
| New | +$416K |
|
1303
Park National Corp
PRK
$3.75B
| $391K | ﹤0.01% |
3,300
| – | – |
|
1304
Erie Indemnity
ERIE
$12.8B
| $389K | ﹤0.01% |
1,679
-476
| -22% | -$114K |
|
1305
Preferred Bank
PFBC
$1.25B
| $378K | ﹤0.01% |
6,900
+1,500
| +28% | +$101K |
|
|
HIBB
1306
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $377K | ﹤0.01% |
6,400
+1,300
| +25% | +$87.3K |
|
1307
Alpha and Omega Semiconductor
AOSL
$963M
| $375K | ﹤0.01% |
13,900
+900
| +7% | +$26.1K |
|
1308
MarineMax
HZO
$771M
| $371K | ﹤0.01% |
12,900
-11,400
| -47% | -$358K |
|
|
DAWN
1309
DELISTED
Day One Biopharmaceuticals
DAWN
| $369K | ﹤0.01% |
27,598
-18,734
| -40% | -$366K |
|
|
ALLK
1310
DELISTED
Allakos
ALLK
| $364K | ﹤0.01% |
81,900
+11,300
| +16% | +$72.3K |
|
|
SHOE
1311
Shoe Station Group
SHOE
$428M
| $364K | ﹤0.01% |
14,200
+3,400
| +31% | +$88.7K |
|
|
SKE
1312
Skeena Resources
SKE
$3.34B
| $357K | ﹤0.01% |
58,274
+6,718
| +13% | +$38.7K |
|
1313
Boot Barn
BOOT
$4.84B
| $353K | ﹤0.01% |
4,600
-100
| -2% | -$7.67K |
|
|
AVNS
1314
DELISTED
Avanos Medical
AVNS
| $351K | ﹤0.01% |
+11,800
| New | +$343K |
|
|
LIAN
1315
DELISTED
LianBio American Depositary Shares
LIAN
| $348K | ﹤0.01% |
178,519
| – | – |
|
1316
Ginkgo Bioworks
DNA
$570M
| $347K | ﹤0.01% |
6,523
| – | – |
|
1317
Westlake Corp
WLK
$8.93B
| $347K | ﹤0.01% |
2,990
-140
| -4% | -$16.2K |
|
1318
National Presto Industries
NPK
$982M
| $346K | ﹤0.01% |
4,800
| – | – |
|
1319
ProPetro Holding
PUMP
$1.36B
| $343K | ﹤0.01% |
47,700
| – | – |
|
1320
U-Haul Holding Co Series N
UHAL.B
$12.3B
| $342K | ﹤0.01% |
6,604
-29
| -0.4% | -$1.65K |
|
1321
SOPHiA GENETICS
SOPH
$478M
| $342K | ﹤0.01% |
68,753
+3,800
| +6% | +$12.3K |
|
1322
Seer Inc
SEER
$122M
| $338K | ﹤0.01% |
87,692
-24,640
| -22% | -$113K |
|
|
CRON
1323
Cronos Group
CRON
$1.07B
| $335K | ﹤0.01% |
174,262
-335,482
| -66% | -$753K |
|
|
VTLE
1324
DELISTED
Vital Energy
VTLE
| $332K | ﹤0.01% |
+7,300
| New | +$365K |
|
1325
nCino
NCNO
$2.07B
| $332K | ﹤0.01% |
13,410
| – | – |
|
Similar funds
VAM
TD Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, TD Asset Management held 1,503 positions worth $82.9B, up 2.3% from $81B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
TD Asset Management withdrew a net $3.2B in Q1 2023, closing 76 positions and reducing 567 holdings. Its most notable exit was Canadian Pacific Kansas City, an estimated $990M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
Against the trend, TD Asset Management opened a new position in Novo Nordisk worth $25.2M.
- TD Asset Management's largest Q1 2023 buy was Novo Nordisk: 316,140 shares worth $25.2M.
- TD Asset Management added most to Merck in Q1 2023, an estimated $256M increase.
- TD Asset Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $226M.
- TD Asset Management fully exited Canadian Pacific Kansas City in Q1 2023, selling an estimated $990M.
- TD Asset Management's ten largest holdings make up 27% of its $82.9B portfolio in Q1 2023.
- TD Asset Management opened 58 new positions and closed 76 in Q1 2023.
- TD Asset Management's portfolio value rose 2.3% quarter-over-quarter to $82.9B.
Based on TD Asset Management's 13F filing for Q1 2023, filed 10 May 2023.